Optimal Use of Sandimmun in Nephrotic Syndrome

Since 1978, when Sandimmun was first used in humans, greatexperience has been gathered in clinical transplantation bythe treatment of about half a million patients.The experience with Sandimmun in nephrotic syndrome is putinto perspective and compared with alternatives such ascorticosteroids and cytotoxic agents. Sandimmun may beregarded as a leap forward in the treatment of thatpopulation of patients that do not satisfactorily respond tosteroids. The possibility of drastically reducing the use ofcorticosteroids, particularly in children, is perhaps themost attractive feature of Sandimmun.This book gives the results ofa worldwide clinicalprogramme. It includes authors' personal experience as wellas an analysis of all data made available. A carefulassessment of reported side effects is also given.